Paul K. Stockman

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth et al. · JAMA Oncology · 2020 · 628 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Michele Maio, Arnaud Scherpereel, Luana Calabrò et al. · The Lancet Oncology · 2017 · 424 citations

Medicine, Oncology, Pharmacotherapy +11

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

Ronald B. Natale, David Bodkin, Ramaswamy Govindan et al. · Journal of Clinical Oncology · 2009 · 226 citations · Full text

Medicine, Oncology, Pharmacology +17

A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification

Eric Van Cutsem, Yu Jeong Bang, Wasat Mansoor et al. · Annals of Oncology · 2017 · 187 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

David Planchard, Niels Reinmuth, Jürgen R. Fischer et al. · Annals of Oncology · 2020 · 161 citations · Full text

Medicine, Oncology, Pharmacotherapy +16